A polymorphism in FAS gene promoter associated with increased risk of nasopharyngeal carcinoma and correlated with anti-nuclear autoantibodies induction

Cancer Letters

Volumn 233, Issue 1, 2006, Pages 21-27

  Bel Hadj Jrad, Besma ^a,b   Mahfouth, Wijden ^a   Bouaouina, Noureddine ^a,c   Gabbouj, Sallouha ^a   Ahmed, Slim Ben ^c   Ltaïef, Mondher ^a   Jalbout, Majida ^a   Chouchane, Lotfi ^a  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b UNIVERSITY OF MONASTIR   (Tunisia)

^c FARHAT HACHED HOSPITAL   (Tunisia)

Author keywords

Apoptosis; Autoantibodies; FAS; Nasopharyngeal carcinoma; Polymorphism

Indexed keywords

ANTINUCLEAR ANTIBODY; CYTOSKELETON PROTEIN; FAS ANTIBODY; FAS ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; NUCLEAR PROTEIN; PROTEIN ANTIBODY;

ADULT; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNITY; CANCER RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; FEMALE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IMMUNE RESPONSE; IMMUNOFLUORESCENCE TEST; MALE; NASOPHARYNX CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; TUNISIA; VIRUS CARCINOGENESIS;

ADULT; AGED; ANTIBODIES, ANTINUCLEAR; ANTIGENS, CD95; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RISK FACTORS;

HUMAN HERPESVIRUS 4;

EID: 32244446689     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.02.037     Document Type: Article

References (44)

1. G. Klein The relationship of the virus to nasopharyngeal carcinoma in the Epstein-Barr virus M.A. Epstein B.G. Achong 1979 Springer Berlin 339 350
2. H. Wolf, H. Zur Hausen, and V. Becker EB viral genomes in epithelial nasopharyngeal carcinoma cells Nature 244 1973 245 247
3. G. Klein, B.C. Giovanella, T. Lindahl, P.J. Fialkow, S. Singh, and J.S. Stehlin Direct evidence for the presence of Epstein-Barr virus DNA and nuclear antigen in malignant epithelial cells from patients with poorly differentiated carcinoma of the nasopharynx Proc. Natl Acad. Sci. USA 71 1974 4737 4741
4. D. Jeannel, G. Bouvier, A. Hubert, Nasopharyngeal carcinoma: an epidemiological approach to carcinogenesis. Infection and Human Cancer, in: Cancer Surveys, Imperial Cancer Research Fund 33 (1999) 125-155.
5. C.A. Stiller International variations in the incidence of childhood carcinomas Cancer Epidemiol. Biomarkers Prev. 3 1994 305 310
6. M. Jalbout, B. Bel Hadj Jrad, N. Bouaouina, J. Gargouri, S. Yacoub, and A. Zakhama Chouchane, Autoantibodies to tubulin are specifically associated with the young age onset of the nasopharyngeal carcinoma Int. J. Cancer 101 2002 146 150
7. N. Itoh, S. Yonehara, A. Ishii, M. Yonehara, S. Mizushima, and M. Sameshima The polypeptide encoded by the cDNA for human cell surface antigen FAS can mediate apoptosis Cell 66 1991 233 243
8. T. Susa, T. Takahashi, P. Golstein, and S. Nagata Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family Cell 75 1993 1169 1178
9. M. Muschen, U. Warskulat, T. Peters-Regehr, J. Bode, R. Kubitz, and D. Hussinger Involvement of CD95 (Apo-1/Fas) ligand expressed by rat Kupffer cells in hepatic immunoregulation Gastroenterology 116 1999 666 677
10. M.M. Keane, S.A. Ettenberg, G.A. Lowrey, E.K. Ruussell, and S. Lipkowitz Fas expression and function in normal and malignant breast cell lines Cancer Res. 56 1996 4791 4798
11. R. Koomagi, and M. Volm Expression of Fas (CD95/Apo-1) and Fas ligand in lung cancer, its prognostic and predictive relevance Int. J. Cancer 84 1999 239 243
12. S.S. Metkar, K.N. Naresh, A.A. Redar, C.S. Soman, S.H. Advani, and J.J. Nadkarni Expression of Fas and Fas ligand in Hodgkin's disease Leuk. Lymphoma 33 1999 521 530
13. M. Muschen, C. Moers, U. Warskulat, R. Josien, J. Even, and A. Lim CD95 ligand expression in dedifferentiated breast cancer J. Pathol. 189 1999 378 386
14. M. Muschen, U. Warskulat, J. Even, D. Niederacher, and M.W. Beckmann CD95 ligand expression as a mechanism of immune escape in breast cancer Immunology 99 2000 69 77
15. T. Lamy, J.H. Liu, T.H. Landowski, W.S. Dalton, and T.P. Loughran Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3+ large granular lymphocyte leukemia Blood 92 1998 4771 4777
16. L.L. Loro, O.K. Vintermyr, A.C. Johannesen, P.G. Liavaag, and R. Jonsson Suppression of Fas receptor and negative correlation of Fas ligand with differentiation and apoptosis in oral squamous cell carcinoma J. Oral Pathol. Med. 28 1999 82 87
17. M.W. Bennett, J. O'Connell, G.C. O'Sullivan, C. Brady, D. Roche, J. Collins, and F. Shanahan The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma J. Immunol. 160 1998 5669 5675
18. F. Rieux-Laucat, F. Le Deist, C. Hivroz, I.A. Roberts, K.M. Debatin, A. Fischer, and J.P. De Villartay Mutation in Fas associated with human lymphoproliferative syndrome and autoimmunity Science 268 1995 1347 1349
19. G.H. Fisher, F.J. Rosenberg, S.E. Straus, J.K. Dale, L.A. Middletn, and A.Y. Lin Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome Cell 81 1995 935 946
20. A.I. Aspinall, A. Pinto, I.A. Auer, P. Bridges, J. Luider, and L. Dimnik Identification of new Fas mutations in a patient with autoimmune lymphoproliferative syndrome (ALPS) and eosinophilia Blood Cells Mol. Dis. 25 1999 227 238
21. T.H. Landowski, N. Qu, I. Buyuksal, J.S. Painter, and W.S. Dalton Mutation in the Fas antigen in patients with multiple myeloma Blood 90 1997 4266 4270
22. L.L. Delehanty, J.A. Payne, S.N. Farrow, R. Brown, and B.R. Champion Apoptosis in Fas-resistant, T cell receptor-sensitive human leukaemic T-cell clone Immunology 90 1997 383 387
23. T. Maeda, Y. Yamada, R. Moriuchi, K. Sugahara, K. Tsuruda, and T. Joh Fas gene mutation in the progression of adult T cell Leukemia J. Exp. Med. 189 1999 1063 1071
24. S.H. Lee, M.S. Shin, W.S. Park, S.Y. Kim, S.M. Dong, and J.H. Pi Alteration of Fas (Apo-1/CD95) gene in transitional cell carcinomas of urinary bladder Cancer Res. 59 1999 3068 3072
25. S.H. Lee, M.S. Shin, W.S. Park, H.S. Kim, J.Y. Han, and G.S. Park Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer Oncogene 18 1999 3754 3760
26. M.S. Shin, W.S. Park, S.Y. Kim, S.J. Kang, K.Y. Song, and J.Y. Park Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma Am. J. Pathol. 154 1999 1785 1791
27. S.H. Lee, M.S. Shin, H.S. Kim, W.S. Park, S.Y. Kim, and J.J. Jang Somatic mutations of Fas (Apo-1/CD95) gene in cutaneous squamous cell carcinoma arising from a burn scar J. Invest. Dermatol. 114 2000 122 126
28. J. Cheng, T. Zhou, C. Liu, J.P. Shapiro, M.J. Brauer, and M.C. Kiefer Protection from Fas mediated apoptosis by a soluble form of the Fas molecule Science 263 1994 1759 1762
29. D.P.M. Hughes, and N.I. Crispe A naturally occurring soluble isoform of murine Fas generated by alternative splicing J. Exp. Med. 182 1995 1395 1401
30. M. Muschen, U. Warskulat, D. Hussinger, C. Moers, D. Simon, and J. Even Deranged CD95 system in a case of Churg-Strauss vasculitis Gastroenterology 114 1998 1351 1352
31. M. Muschen, U. Warskulat, A. Perniok, J. Even, C. Moers, and B. Kismet Involvement of soluble CD95 in Churg-Strauss syndrome Am. J. Pathol. 155 1999 915 925
32. U. Takayuki, T. Masakazu, and T. Takeshi Circulating soluble Fas concentration in breast cancer patients Clin. Cancer Res. 5 1999 3529 3533
33. R. Konno, T. Takano, S. Sato, and A. Yajima Serum soluble Fas level as a prognostic factor in patients with gynecological malignancies Clin. Cancer Res. 6 2000 3576 3580
34. U. Ugurel, G. Rappl, W. Tilgen, and U. Reinhold Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients Clin. Cancer Res. 7 2001 1282 1286
35. Q.R. Huang, D. Morris, and N. Manolios Identification and characterisation of polymorphism in the promoter region of the human Apo-1/Fas (CD95) gene Mol. Immunol. 34 1997 577 582
36. S. Kanemitsu, K. Ihara, A. Saifddin, T. Otsuka, T. Takeuchi, and J. Nagayama A functional polymorphism in Fas (CD95/Apo-1) gene promoter associated with systemic lupus erythematosus J. Rheumatol. 29 2002 1183 1188
37. K. Shanmugaratnam, C.Y. Tye, E.H. Goh, and K.B. Chia Etiological factors in nasopharyngeal carcinoma: a hospital-based, retrospective, case-control, questionnaire study IARC Sci. Publ. 20 1978 199 212
38. O. Olerup, and H. Zetterquist HLA-DR typing by PCR amplification with sequence specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation Tissue Antigens 39 1992 225 235
39. A.L. McDerrmott, S.N. Dutt, and J.C. Watkinson The aetiology of nasopharyngeal carcinoma Clin. Otolaryngol. 26 2001 82 92
40. H.C. Lai, H.K. Sytwu, C.A. Sun, M.H. Yu, C.P. Yu, and H.S. Lui Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis Int. J. Cancer 103 2003 221 225
41. R. Watanabe-Fukunaga, C.I. Brannan, N.G. Copeland, N.A. Jenkins, and S. Nagata Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis Nature 356 1992 314 317
42. A.V. Chervonsky, Y. Wang, F.S. Wong, I. Visintin, R.A. Flavell, C.A.J. Janeway, and L.A. Matis The role of Fas in autoimmune diabetes Cell 89 1997 17 24
43. C. Giordan, G. Stassi, R. De Maria, M. Todaro, P. Richiusa, and G. Papoff A potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis Science 275 1997 960 963
44. Y.H. Lee, Y.R. Kim, J.D. Ji, J. Sohn, and G.G. Song Fas promoter -670 polymorphism is associated with development of anti-RNP antibodies in systemic lupus erythematosus J. Rheumatol. 28 2001 2008 2011